Latest From Biotech Now

Opportunity or Apocalypse? Prophecies for 2012

BIF Closing Plenary

On day two of the BIO Investor Forum in San Francisco, Calif., attendees were eager to participate in the Closing Plenary. Historically, this session draws the biggest crowd of the conference and this year was no exception. Speaking to a packed audience, with standing room only, the panelists engaged in a lively discussion about the state of the industry and what is in the cards for 2012. Both Bryan Roberts, PhD, Partner, Venrock and Matthew Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

Repositioning Drugs for Parkinson’s Disease

Parkinson's Research

Last month, The Michael J. Fox Foundation (MJFF) announced the launch of its Repositioning Drugs for PD 2012 program. The program follows a successful 2011 during which the Foundation funded nine awards totaling $3.4 million repositioning existing drugs that could benefit Parkinson’s disease patients. The program seeks projects that will test drugs that are either already FDA-approved or that have been proven safe in a clinical trial for a certain indication, to determine whether the Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Commercialization and Job Creation in the Biotechnology Sector

Doug Crawford

It’s tough presenting programs on technology transfer because so much has already been said that it’s hard to find something new. However, that was not a problem this week in San Francisco at the BIO Technology Transfer Symposium. The Symposium began with an overview of the efforts by the Obama Administration to spur innovation including funding macro and micro grants to encourage the development of regional technology clusters, and proof of concept centers to help Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Beyond the ABCs of ADCs

Antibody

The recent FDA approval of Seattle Genetics’ antibody, Adcetris, has cast the spotlight on Antibody Drug Conjugates (ADC), leaving experts to contemplate whether this is the peak for ADCs. If history has its say though, the spotlight won’t be flickering anytime soon. Experts in this specialized antibody field discussed the latest developments and lessons of bringing ADCs through the clinic at this week’s 10th Annual BIO Investor Forum. Antibody drug conjugates hold enormous potential for treating Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Resistance is Futile – SuperDrugs for SuperBugs

800px-Acinetobacter_baumannii

“MRSA’s kill 100,000 people a year, more than AIDS,” said Mark Leuchetenberger, President and CEO, Rib-X Pharmaceuticals, Inc. With new superbugs on the rise and new superdrugs continuing to decline, the antibacterial drug discovery market is anyone’s for the taking. Attendees of the 10th Annual BIO Investor Forum participating in the Infectious Disease Therapeutic Workshop heard from an engaging panel that seemed to agree the economics of this category are driven by two things: society expects Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,